# A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

> **NCT04786262** · PHASE3 · RECRUITING · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 52 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 1
- Impaired Hypoglycemic Awareness
- Severe Hypoglycemia

## Interventions

- **BIOLOGICAL:** VX-880

## Key facts

- **NCT ID:** NCT04786262
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-29
- **Primary completion:** 2027-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04786262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04786262, "A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04786262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*